Butcher Arthur C 4
4 · BOSTON SCIENTIFIC CORP · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
Boston Scientific (BSX) EVP Arthur C. Butcher Receives Awards, Shares Withheld
What Happened
Arthur C. Butcher, EVP & Group President, MedSurg & APAC at Boston Scientific (BSX), received shares when performance- and time-based awards vested/converted in mid-February 2026. A total of 58,716 shares were issued to him (50,760 from awards + 7,956 from derivative conversions). To cover tax withholding obligations, 27,914 shares were surrendered/withheld at $74.73 per share, generating proceeds of approximately $2,086,014. Net shares issued to him after withholdings were 30,802.
Key Details
- Transaction dates: conversions/awards dated Feb 13–16, 2026; Form 4 filed Feb 18, 2026.
- Awards/grants: two award entries of 25,380 shares each (performance share programs) and three derivative conversions of 2,237 / 3,173 / 2,546 shares. (Total issued = 58,716.)
- Tax withholding (share surrender): 25,150 + 1,535 + 1,229 = 27,914 shares withheld at $74.73/share for total cash value ~$2,086,014. (Transaction code F = payment of tax liability.)
- Net new shares retained by Butcher after withholding: 30,802.
- Notable footnotes: awards trace to Feb 14, 2023 performance-share grants (F1, F2) that vested based on three-year performance through Dec 31, 2025; RSU = one share per unit (F3); some awards are payable in installments per the footnotes (F5–F7).
- Filing: Form 4 filed Feb 18, 2026 reporting the Feb 13–16 activity (the filing date is shown on the form).
Context
- This was primarily award vesting/conversion and related tax withholding — not an open-market purchase or discretionary sale. In filings, conversion/exercise lines (code M) reflect derivative awards converting to common stock, and withholding (code F) reflects shares surrendered to satisfy tax obligations (a common, routine practice).
- Such automatic withholding/surrender of shares for taxes is standard and does not, by itself, indicate a bullish or bearish signal.
- No post-transaction total holdings were specified in the filing; consult the full Form 4 for complete holding balances and any additional footnote detail.
Insider Transaction Report
Form 4
Butcher Arthur C
EVP& Grp Pres, MedSurg & APAC
Transactions
- Award
Common Stock
[F1]2026-02-13+25,380→ 50,370 total - Award
Common Stock
[F2]2026-02-13+25,380→ 75,750 total - Exercise/Conversion
Common Stock
[F3]2026-02-13+2,237→ 77,987 total - Tax Payment
Common Stock
2026-02-13$74.73/sh−25,150$1,879,460→ 52,837 total - Exercise/Conversion
Common Stock
[F3]2026-02-14+3,173→ 56,010 total - Tax Payment
Common Stock
2026-02-14$74.73/sh−1,535$114,711→ 54,475 total - Exercise/Conversion
Common Stock
[F3]2026-02-16+2,546→ 57,021 total - Tax Payment
Common Stock
2026-02-16$74.73/sh−1,229$91,843→ 55,792 total - Exercise/Conversion
Restricted Stock Units
[F3][F5]2026-02-13−2,237→ 6,713 totalExp: 2029-02-13→ Common Stock (2,237 underlying) - Exercise/Conversion
Restricted Stock Units
[F3][F6]2026-02-14−3,173→ 3,173 totalExp: 2027-02-14→ Common Stock (3,173 underlying) - Exercise/Conversion
Restricted Stock Units
[F3][F7]2026-02-16−2,546→ 0 totalExp: 2026-02-16→ Common Stock (2,546 underlying)
Holdings
- 13,354(indirect: By 401(k))
Common Stock
[F4]
Footnotes (7)
- [F1]On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
- [F2]On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
- [F3]Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- [F4]Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
- [F5]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.
- [F6]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.
- [F7]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.
Signature
/s/ Susan Thompson, Attorney-in-Fact|2026-02-18